$ImmunityBio (IBRX.US)$
News of individual stocks on 2/14
The UK Medicines and Medical Supplies Regulatory Agency announced that it has accepted the marketing authorization application for Anktiva® for the treatment of patients with BCG-resistant non-muscle invasive bladder cancer.
From the company site, ANKTIVA® is the first immunotherapy approved by the FDA in the USA 🌈 that activates a type of cell called natural killer (NK) cells, which are part of the body's natural immune system, to attack and kill non-muscle invasive bladder cancer (NMIBC) cells. 1,2 ANKTIVA is a combination therapy with Bacillus Calmette-Guerin (BCG), the standard treatment for NMIBC, targeting NMIBC patients for whom BCG alone has been ineffective or those whose NMIBC has recurred after initial successful treatment. These patients are referred to as BCG non-responsive NMIBC. ANKTIVA + BCG is an option for patients with BCG non-responsive NMIBC carcinoma in situ (CIS) who are not candidates for or do not wish surgical removal of the bladder.

$Metsera (MTSR.US)$
Since going public, it has been consistently on the rise 🤫.

$KULR Technology (KULR.US)$ I have not yet moved beyond the domain of Gainianbankuai, but I hope that if any of the technically materialized technologies can generate revenue, it will suddenly transform.
I have a small image of Mitsubishi Heavy Industries as it includes almost all the current hot topics.